Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 35.2% in February

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 59,700 shares, a decline of 35.2% from the February 13th total of 92,200 shares. Currently, 3.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 376,300 shares, the short-interest ratio is currently 0.2 days.

Avenue Therapeutics Trading Up 9.7 %

Shares of Avenue Therapeutics stock opened at $0.85 on Friday. The company has a 50-day moving average of $1.44 and a two-hundred day moving average of $1.93. Avenue Therapeutics has a 12-month low of $0.72 and a 12-month high of $13.13. The stock has a market cap of $1.74 million, a PE ratio of 0.05 and a beta of -0.29.

Institutional Trading of Avenue Therapeutics

A hedge fund recently bought a new stake in Avenue Therapeutics stock. Boothbay Fund Management LLC purchased a new position in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 41,089 shares of the company’s stock, valued at approximately $82,000. Boothbay Fund Management LLC owned about 2.00% of Avenue Therapeutics as of its most recent SEC filing. 17.34% of the stock is owned by hedge funds and other institutional investors.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.